CN112996564A - 靶向il-1r1和nlpr3的双特异性抗体 - Google Patents

靶向il-1r1和nlpr3的双特异性抗体 Download PDF

Info

Publication number
CN112996564A
CN112996564A CN201980074106.7A CN201980074106A CN112996564A CN 112996564 A CN112996564 A CN 112996564A CN 201980074106 A CN201980074106 A CN 201980074106A CN 112996564 A CN112996564 A CN 112996564A
Authority
CN
China
Prior art keywords
seq
modulator
antibody
nlrp3
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980074106.7A
Other languages
English (en)
Chinese (zh)
Inventor
V·麦吉利根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ulster University
Original Assignee
Ulster University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ulster University filed Critical Ulster University
Publication of CN112996564A publication Critical patent/CN112996564A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980074106.7A 2018-09-14 2019-09-16 靶向il-1r1和nlpr3的双特异性抗体 Pending CN112996564A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1815045.8 2018-09-14
GBGB1815045.8A GB201815045D0 (en) 2018-09-14 2018-09-14 Bispecific antibody targeting IL-1R1 and NLPR3
PCT/EP2019/074744 WO2020053446A1 (en) 2018-09-14 2019-09-16 Bispecific antibody targeting il-1r1 and nlpr3

Publications (1)

Publication Number Publication Date
CN112996564A true CN112996564A (zh) 2021-06-18

Family

ID=64013420

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980074106.7A Pending CN112996564A (zh) 2018-09-14 2019-09-16 靶向il-1r1和nlpr3的双特异性抗体
CN201980074059.6A Pending CN112996563A (zh) 2018-09-14 2019-09-16 靶向il-1r1和nlpr3的双特异性抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980074059.6A Pending CN112996563A (zh) 2018-09-14 2019-09-16 靶向il-1r1和nlpr3的双特异性抗体

Country Status (7)

Country Link
US (2) US12264201B2 (enExample)
EP (2) EP3849662A1 (enExample)
JP (3) JP7517702B2 (enExample)
CN (2) CN112996564A (enExample)
AU (2) AU2019338955B2 (enExample)
GB (1) GB201815045D0 (enExample)
WO (2) WO2020053446A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119925593A (zh) * 2023-06-05 2025-05-06 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
JP2024501033A (ja) * 2020-12-28 2024-01-10 エムディー ヘルスケア インコーポレイテッド ミクロコッカス・ルテウス由来細胞外小胞を含む眼疾患の予防または治療用組成物
US20250382341A1 (en) * 2022-12-30 2025-12-18 The Regents Of The University Of California Methods and compositions of in vivo engineering of t-cells to anti-inflammatory cells and therapeutic applications there of
CN120535628B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的纯化方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123493A2 (en) * 2014-02-13 2015-08-20 Northwestern University Compositions and methods for modulatuion of immune response
CN105061598A (zh) * 2008-11-07 2015-11-18 米迪缪尼有限公司 抗il-1r1结合成员

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1266004A2 (en) 2000-02-17 2002-12-18 Millennium Pharmaceuticals, Inc. Molecules of the pyrin domain protein family and uses thereof
AU2001296333A1 (en) 2000-09-26 2002-04-08 The Burnham Institute Paad domain-containing polypeptides, encoding nucleic acids, and methods of use
WO2007077042A1 (en) 2006-01-06 2007-07-12 Topotarget Switzerland Sa New method for the treatment of gout or pseudogout
US20080008652A1 (en) 2006-01-10 2008-01-10 The Regents Of The University Of Michigan Methods and compositions for mediation of immune responses and adjuvant activity
FR2937339B1 (fr) 2008-10-21 2013-02-15 Univ Bourgogne Procede de detection de la maladie atheromateuse.
WO2011109459A2 (en) 2010-03-04 2011-09-09 University Of Miami Compositions, kits and methods for determining efficacy of a therapeutic agent and treating hair and skin diseases
CA2808185A1 (en) 2010-08-13 2012-02-16 Genentech, Inc. Antibodies to il-1.beta. and il-18, for treatment of disease
US9707272B2 (en) * 2011-07-12 2017-07-18 Universitat Zurich Method for the treatment of acne by administering IL-1β antibody
US10633451B2 (en) * 2012-02-03 2020-04-28 Hoffmann-La Roche Inc. Bispecific antibody molecules with antigen-transfected T-cells and their use in medicine
EP2812697B1 (en) 2012-02-06 2017-03-22 University of Miami Innate immune proteins as biomarkers for cns injury
EP2825561A4 (en) 2012-03-15 2016-03-09 Permeon Biolog Inc CELL PENETRATING COMPOSITIONS FOR THE DISPOSAL OF INTRA-CELLULAR ANTIBODIES AND ANTIBODY-RELATED UNITS AND METHODS OF USE
AU2015204558B2 (en) * 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
CN104258398B (zh) * 2014-10-14 2017-12-22 中国科学技术大学 Drd1及其激动剂在制备治疗nlrp3炎症小体相关炎症性疾病药物中的用途
US20170145412A1 (en) 2015-11-04 2017-05-25 Idera Pharmaceuticals, Inc. Compositions for inhibiting nlrp3 gene expression and uses thereof
JP2019069905A (ja) * 2016-02-29 2019-05-09 国立大学法人大阪大学 組織損傷治療剤
US20200115358A1 (en) * 2016-03-11 2020-04-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Icariin and icaritin derivatives
WO2018022982A1 (en) * 2016-07-29 2018-02-01 Trustees Of Boston University Age-associated clonal hematopoiesis accelerates cardio-metabolic disease development

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105061598A (zh) * 2008-11-07 2015-11-18 米迪缪尼有限公司 抗il-1r1结合成员
WO2015123493A2 (en) * 2014-02-13 2015-08-20 Northwestern University Compositions and methods for modulatuion of immune response

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LIANG FENG ET AL.: "NLRP3 inflammasome in retinal ganglion cell loss in optic neuropathy", 《NEURAL REGENERATION RESEARCH》, vol. 11, no. 7, pages 1077, XP055645694, DOI: 10.4103/1673-5374.187036 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119925593A (zh) * 2023-06-05 2025-05-06 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
CN119925593B (zh) * 2023-06-05 2025-11-25 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂

Also Published As

Publication number Publication date
JP2024125385A (ja) 2024-09-18
AU2019338955B2 (en) 2026-03-19
EP3849661A1 (en) 2021-07-21
AU2019338674A1 (en) 2021-04-22
US12227579B2 (en) 2025-02-18
AU2019338955A1 (en) 2021-04-15
JP2022500457A (ja) 2022-01-04
US20220041739A1 (en) 2022-02-10
US20220033507A1 (en) 2022-02-03
GB201815045D0 (en) 2018-10-31
JP2022500455A (ja) 2022-01-04
WO2020053446A1 (en) 2020-03-19
JP7517702B2 (ja) 2024-07-17
CN112996563A (zh) 2021-06-18
AU2019338674B2 (en) 2026-02-05
EP3849662A1 (en) 2021-07-21
JP7645544B2 (ja) 2025-03-14
WO2020053447A1 (en) 2020-03-19
US12264201B2 (en) 2025-04-01

Similar Documents

Publication Publication Date Title
JP7645544B2 (ja) Ｉｌ－１ｒ１およびｎｌｐｒ３標的化二重特異性抗体
TWI747922B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
CN111356701B (zh) 抗α-突触核蛋白抗体及其用途
JP2020188765A (ja) Ｌｏｘ１特異的結合タンパク質及びその使用
JP2022514290A (ja) 改変抗体ｆｃおよび使用方法
CN111886251A (zh) 抗a-syn/igf1r的双特异性抗体及其用途
TWI547501B (zh) 用於中和血管內皮生長因子之重組單株抗體vNAR
KR20240056422A (ko) 인간 안지오포이에틴-2에 특이적으로 결합하는 제1 항원 결합 부위를 포함하는 이중특이적 항체 및 그 응용
HK40096583A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
HK40103027A (zh) 抗a-syn/igf1r的双特异性抗体及其用途
HK40022840B (zh) 抗α-突触核蛋白抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210618